374791-02-3

Basic information

• Product Name: (R)-N-FMOC-AZETIDINE-2-CARBOXYLIC ACID, 95%, (98% E.E.)
• Synonyms: (R)-N-FMOC-AZETIDINE-2-CARBOXYLIC ACID, 95%, (98% E.E.);(R)-N-Fmoc-Azetidine-2-carboxylicacid(e.e.);(R)-N-FMOC-Azetidine-2-carboxylic acid, 98% ee, 95%;FMoc-(R)-azetidine-2-carboxylic acid;(R)-1-(((9H-fluoren-9-yl)Methoxy)carbonyl)azetidine-2-carboxylic acid;(2R)-1-FMoc-2-azetidinecarboxylic acid;1,2-Azetidinedicarboxylic acid, 1-(9H-fluoren-9-ylmethyl) ester, (2R)-;(2R)-1-(9H-fluoren-9-ylmethoxycarbonyl)azetidine-2-carboxylic acid
• CAS NO: 374791-02-3
• Molecular Formula: C19H17NO4
• Molecular Weight: 323.34258
• Mol File: 374791-02-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 139.4°C
• Boiling Point: 461.82°C (rough estimate)
• Flash Point: 282.3°C
• Appearance: /
• Density: 1.2675 (rough estimate)
• Vapor Pressure: 1.24E-12mmHg at 25°C
• Refractive Index: 1.5000 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.95±0.20(Predicted)
• CAS DataBase Reference: (R)-N-FMOC-AZETIDINE-2-CARBOXYLIC ACID, 95%, (98% E.E.)(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-FMOC-AZETIDINE-2-CARBOXYLIC ACID, 95%, (98% E.E.)(374791-02-3)
• EPA Substance Registry System: (R)-N-FMOC-AZETIDINE-2-CARBOXYLIC ACID, 95%, (98% E.E.)(374791-02-3)

Safety Data

• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 374791-02-3(Hazardous Substances Data)

Usage

Chemical Properties

white powder

InChI:InChI=1/C19H17NO4/c21-18(22)17-9-10-20(17)19(23)24-11-16-14-7-3-1-5-12(14)13-6-2-4-8-15(13)16/h1-8,16-17H,9-11H2,(H,21,22)/p-1/t17-/m1/s1

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 2133-34-8 (2S)-azetidine-2-carboxylic acid 
• 497-19-8 sodium carbonate 
• 7729-30-8 (R)-azetidine-2-carboxylic acid 

Downstream Products

• 1440521-91-4 C₃₈H₆₄N₁₂O₈ 
• 105751-19-7 1-(9H-Fluoren-9-ylmethyl) hydrogen 1,2-piperidine dicarboxylate 

Relevant articles and documents

2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors

Disclosed are novel amino acid derivatives of the formula: STR1 wherein X is H, amidino or STR2 Y is H, amino or STR3 Z is STR4 OR1 or a naturally occurring L-amino acid, bounded to the carbon atom at the α-amino position; R is alkyl, aryl or aralkyl; R1 and R2 are independently H, alkyl, aryl, aralkyl or allyl; m is 1 through 5; n is 0 through 4; and pharmaceutically acceptable salts thereof, that inhibit platelet aggregation and thrombus formation in mammalian blood.